Viking Therapeutics, Inc. (FRA:1VT)

Viking Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 8, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	3,109	4,331	1,684	675	316	336
Market Cap Growth	-31.46%	157.18%	149.68%	113.16%	-5.75%	-34.98%
Enterprise Value	2,495	3,434	1,345	531	126	127
Last Close Price	28.00	38.24	17.32	8.56	4.07	4.70
PB Ratio	5.12	5.09	5.34	4.96	1.78	1.68
P/TBV Ratio	5.12	5.09	5.34	4.96	1.78	1.68
Debt / Equity Ratio	0.00	0.00	0.00	0.01	0	0.00
Quick Ratio	27.41	32.93	18.92	7.09	23.02	20.48
Current Ratio	28.34	33.09	19.19	7.61	23.98	21.12
Return on Equity (ROE)	-29.23%	-17.90%	-34.79%	-39.67%	-24.65%	-15.15%
Return on Assets (ROA)	-20.48%	-14.77%	-23.47%	-23.19%	-14.90%	-9.86%
Return on Capital (ROIC)	-21.12%	-15.32%	-25.38%	-25.21%	-15.58%	-10.21%
Return on Capital Employed (ROCE)	-38.50%	-17.10%	-28.90%	-48.00%	-27.60%	-17.50%
Earnings Yield	-6.51%	-2.45%	-4.61%	-9.55%	-15.28%	-9.62%
Buyback Yield / Dilution	-5.48%	-15.57%	-22.79%	0.47%	-6.34%	-0.89%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.